{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:18:04Z","timestamp":1788164284219,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"73","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA199334"],"award-info":[{"award-number":["U01CA199334"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Screening recommendations in the United States have not been modified for women who have been vaccinated against human papillomavirus (HPV). Using 3 independent Cancer Intervention and Surveillance Modeling Network (CISNET) models (Policy1-Cervix, Harvard and STDSIM-MISCAN), we evaluated the impact of switching from 3-yearly cytology-based screening for ages 21-65 (\u201ccytology alone\u201d) to primary-HPV-16\/18 screening for ages 25-65 every 5-years (\u201cstandardized 5-yearly HPV screening\u201d), or every 8-10\u2009years for younger vaccinated cohorts (\u201ctailored HPV screening\u201d). Compared to cytology alone, switching to standardized 5-yearly HPV screening for all women would reduce total cervical cancer deaths over the period 2020-2099 by 9%-14% and total colposcopies by 15%-49%, and achieve cervical cancer elimination by 2030-2037, 4\u2009years earlier than cytology screening alone. Compared to cytology alone, tailored HPV screening would reduce cervical cancer deaths over the period 2020-2099 by 2%-14%, colposcopies by 30%-59%, and achieve elimination by 2030-2040, 1-4-years earlier. In conclusion, primary HPV screening in all women would be associated with improved health outcomes and would reduce colposcopy referrals in the longer term compared to older, cytology approaches. Tailoring the HPV screening interval to vaccination status has potential to increase efficiencies and maintain effectiveness and elimination timing.<\/jats:p>","DOI":"10.1093\/jncimonographs\/lgag008","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:46:48Z","timestamp":1776858408000},"page":"126-136","source":"Crossref","is-referenced-by-count":0,"title":["Benefits, harms, and cervical cancer elimination timing of human papillomavirus screening approaches tailored to birth cohort as a proxy for vaccination status in the United States: a comparative modeling study"],"prefix":"10.1093","volume":"2026","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0671-7295","authenticated-orcid":false,"given":"Kate T","family":"Simms","sequence":"first","affiliation":[{"name":"Cancer Elimination Collaboration, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney , Sydney, 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00ebl","family":"de Bondt","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus Medical Center , Rotterdam, 3015,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Killen","sequence":"additional","affiliation":[{"name":"Cancer Elimination Collaboration, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney , Sydney, 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sy","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Harvard T.H. Chan School of Public Health , Boston, MA, 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emi","family":"Naslazi","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus Medical Center , Rotterdam, 3015,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Caroline","family":"Regan","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Harvard T.H. Chan School of Public Health , Boston, MA, 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A","family":"Burger","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Harvard T.H. Chan School of Public Health , Boston, MA, 02115,","place":["United States"]},{"name":"Department of Health Management and Health Economics, University of Oslo , Oslo, 0316,","place":["Norway"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J","family":"Kim","sequence":"additional","affiliation":[{"name":"Center for Health Decision Science, Harvard T.H. Chan School of Public Health , Boston, MA, 02115,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan A","family":"Smith","sequence":"additional","affiliation":[{"name":"Cancer Elimination Collaboration, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney , Sydney, 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9419-0452","authenticated-orcid":false,"given":"Inge M C M","family":"de Kok","sequence":"additional","affiliation":[{"name":"Department of Public Health, Erasmus Medical Center , Rotterdam, 3015,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6443-6618","authenticated-orcid":false,"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[{"name":"Cancer Elimination Collaboration, Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney , Sydney, 2006,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026083104013735900_lgag008-B1","author":"World Health Organisation","year":"2020"},{"key":"2026083104013735900_lgag008-B2","first-page":"1","article-title":"Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Markowitz","year":"2014","journal-title":"MMWR Recomm Rep"},{"key":"2026083104013735900_lgag008-B3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.15585\/mmwr.mm6832a3","article-title":"Human papillomavirus vaccination for adults: updated recommendations of the advisory committee on immunization practices","volume":"68","author":"Meites","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B4","first-page":"300","article-title":"Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices","volume":"64","author":"Petrosky","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B5","doi-asserted-by":"crossref","first-page":"djv086","DOI":"10.1093\/jnci\/djv086","article-title":"US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines","volume":"107","author":"Saraiya","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013735900_lgag008-B6","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.acap.2017.09.014","article-title":"Ten years of human papillomavirus vaccination in the United States","volume":"18","author":"Markowitz","year":"2018","journal-title":"Acad Pediatr"},{"key":"2026083104013735900_lgag008-B7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US preventive services task force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"2026083104013735900_lgag008-B8","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1056\/NEJMoa1917338","article-title":"HPV vaccination and the risk of invasive cervical cancer","volume":"383","author":"Lei","year":"2020","journal-title":"N Engl J Med"},{"key":"2026083104013735900_lgag008-B9","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1002\/ijc.30392","article-title":"Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries","volume":"139","author":"Simms","year":"2016","journal-title":"Int J Cancer"},{"key":"2026083104013735900_lgag008-B10","doi-asserted-by":"crossref","first-page":"djw216","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026083104013735900_lgag008-B11","first-page":"101474","article-title":"Optimal cervical cancer screening strategies for unvaccinated and HPV-vaccinated cohorts in the United States: a comprehensive comparative modeling analysis","volume":"58","year":"2026","journal-title":"Lancet Reg Health Am"},{"key":"2026083104013735900_lgag008-B12","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S2468-2667(20)30006-2","article-title":"Projected time to elimination of cervical cancer in the USA: a comparative modelling study","volume":"5","author":"Burger","year":"2020","journal-title":"Lancet Public Health"},{"key":"2026083104013735900_lgag008-B13","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/jnci\/djz227","article-title":"Estimating the natural history of cervical carcinogenesis using simulation models: a CISNET comparative analysis","volume":"112","author":"Burger","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2026083104013735900_lgag008-B14","doi-asserted-by":"crossref","first-page":"e1003534","DOI":"10.1371\/journal.pmed.1003534","article-title":"Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: a cost-effectiveness analysis","volume":"18","author":"Kim","year":"2021","journal-title":"PLoS Med"},{"key":"2026083104013735900_lgag008-B15","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1158\/1055-9965.EPI-13-0973","article-title":"A population-based evaluation of cervical screening in the United States: 2008\u20132011","volume":"23","author":"Cuzick","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2026083104013735900_lgag008-B16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ygyno.2020.05.030","article-title":"Historical and projected hysterectomy rates in the USA: implications for future observed cervical cancer rates and evaluating prevention interventions","volume":"158","author":"Simms","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026083104013735900_lgag008-B17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.15585\/mmwr.mm6533a4","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2015","volume":"65","author":"Reagan-Steiner","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B18","first-page":"997","article-title":"National, state, and local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2008","volume":"58","author":"Centers for Disease Control and Prevention","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B19","first-page":"1018","article-title":"National, state, and local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2009","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B20","first-page":"1117","article-title":"National and state vaccination coverage among adolescents aged 13 through 17 years\u2014United States, 2010","volume":"60","author":"Centers for Disease Control and Prevention","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B21","first-page":"685","article-title":"National and state vaccination coverage among adolescents aged 13-17 years\u2014United States, 2012","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.15585\/mmwr.mm6429a3","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years\u2014United States, 2014","volume":"64","author":"Reagan-Steiner","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026083104013735900_lgag008-B23","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ygyno.2013.12.037","article-title":"Cervical excisional treatment of young women: a population-based study","volume":"132","author":"Kinney","year":"2014","journal-title":"Gynecol Oncol"},{"key":"2026083104013735900_lgag008-B24","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/ijc.29337","article-title":"Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management","volume":"136","author":"Cuzick","year":"2015","journal-title":"Int J Cancer"},{"key":"2026083104013735900_lgag008-B25","first-page":"CD008587","article-title":"Cytology versus HPV testing for cervical cancer screening in the general population","volume":"8","author":"Koliopoulos","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2026083104013735900_lgag008-B26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020\u201399: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026083104013735900_lgag008-B27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","article-title":"Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Canfell","year":"2020","journal-title":"Lancet"},{"key":"2026083104013735900_lgag008-B28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"Lancet"},{"key":"2026083104013735900_lgag008-B29","year":"2019"},{"key":"2026083104013735900_lgag008-B30","doi-asserted-by":"crossref","first-page":"100184","DOI":"10.1016\/j.pvr.2019.100184","article-title":"HPV-FRAME: a consensus statement and quality framework for modelled evaluations of HPV-related cancer control","volume":"8","author":"Canfell","year":"2019","journal-title":"Papillomavirus Res"},{"key":"2026083104013735900_lgag008-B31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1136\/sextrans-2017-053235","article-title":"Acceptability and ease of use of mailed HPV self-collection among infrequently screened women in North Carolina","volume":"94","author":"Anderson","year":"2018","journal-title":"Sex Transm Infect"},{"key":"2026083104013735900_lgag008-B32","article-title":".","volume-title":"FDA Roundup: May 17, 2024","author":"Food","year":"2024"},{"key":"2026083104013735900_lgag008-B33","volume-title":"Draft Recommendation Statement: cervical Cancer: Screening","author":"U.S. Preventive Services Task Force","year":"2024"},{"key":"2026083104013735900_lgag008-B34","doi-asserted-by":"crossref","first-page":"23814683211071093","DOI":"10.1177\/23814683211071093","article-title":"Impact of delaying effective and cost-effective policy decisions: an example from cervical cancer prevention in Norway","volume":"7","author":"Portnoy","year":"2022","journal-title":"MDM Policy Pract"},{"key":"2026083104013735900_lgag008-B35","doi-asserted-by":"publisher","first-page":"497","DOI":"10.7326\/ANNALS-25-03192","article-title":"Optimizing cervical cancer screening by age at vaccination for human papillomavirus: Health and Resource Implications","volume":"179","year":"2026","journal-title":"Ann Intern Med"},{"key":"2026083104013735900_lgag008-B36","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0272989X251332597","article-title":"Optimizing the harms and benefits of cervical screening in a partially vaccinated population in Ontario, Canada: a modeling study","volume":"45","author":"de Bondt","year":"2025","journal-title":"Med Decis Making"},{"key":"2026083104013735900_lgag008-B37","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/jnci\/djae319","article-title":"Disparities in cervical cancer elimination time frames in the United States: a comparative modeling study","volume":"117","author":"Burger","year":"2025","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2026083104013735900_lgag008-B38","author":"World Health Organisation"},{"key":"2026083104013735900_lgag008-B39"},{"key":"2026083104013735900_lgag008-B40","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2214-109X(24)00477-7","article-title":"Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9\u201314 years: results of the long-term extension of the DoRIS randomised trial","volume":"13","author":"Watson-Jones","year":"2025","journal-title":"Lancet Glob Health"},{"key":"2026083104013735900_lgag008-B41","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.vaccine.2024.01.046","article-title":"Evidence for an HPV one-dose schedule","volume":"42(Suppl 2)","author":"Stanley","year":"2024","journal-title":"HPV Introd Implement Case Stud Afr South Asia."},{"key":"2026083104013735900_lgag008-B42","author":"Assistant Secretary for Public Affairs","year":"2026"}],"container-title":["JNCI Monographs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/126\/70870274\/lgag008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncimono\/article-pdf\/2026\/73\/126\/70870274\/lgag008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:01:47Z","timestamp":1788163307000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncimono\/article\/2026\/73\/126\/8776093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":42,"journal-issue":{"issue":"73","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jncimonographs\/lgag008","relation":{},"ISSN":["1052-6773","1745-6614"],"issn-type":[{"value":"1052-6773","type":"print"},{"value":"1745-6614","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,8,1]]}}}